交易 Janux Therapeutics, Inc. - JANX 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.13
• 长仓隔夜仓息调整: -0.02160%
• 短仓隔夜仓息调整: -0.00063%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 0.1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 14
• 开仓: 14.09
• 1 年变化: -74.61%
• 日区间: 13.74 - 14.4

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company''s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.